Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

Piedra, Pedro A.; Gaglani, Manjusha; Kozinetz, Claudia A.; Herschler, Gayla B.; Riggs, Mark; Griffith, Melissa Elliott; Fewlass, Charles; Watts, Matt; Hessel, Colin M.; Cordova, Julie; Glezen, W. Paul

doi:10.1016/j.vaccine.2004.09.025

Cited by 251 publications

(174 citation statements)

References 30 publications

Supporting

Mentioning

158

Contrasting

Unclassified

Order By: Relevance

“…35 years and pneumonia and influenza hospitalization rates in those age 65 years, although vaccine uptake was low in the elderly [37][38][39]. Similar benefits have been reported in modelling studies in the UK and Germany [40,41].…”

Section: Strategies For Improving Vaccination Effectiveness In the Elsupporting

confidence: 67%

The role of vaccination in successful independent ageing

McElhaney¹,

Gavazzi

Flamaing

et al. 2016

European Geriatric Medicine

View full text Add to dashboard Cite

Section: Strategies For Improving Vaccination Effectiveness In the Elsupporting

confidence: 67%

The role of vaccination in successful independent ageing

McElhaney¹,

Gavazzi

Flamaing

et al. 2016

European Geriatric Medicine

View full text Add to dashboard Cite

“…Annual vaccination is the most effective method for preventing influenza and its complications. Influenza vaccines have been used in adult populations for many decades, but the focus on their use in children, for direct5, 6 and indirect protection,4, 7, 8, 9, 10, 11, 12 is a more recent phenomenon. This focus has led to a number of recommendations for universal annual vaccination in healthy children 13, 14.…”

Section: Introductionmentioning

confidence: 99%

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents

Lambert

Chuk

Nissen

et al. 2013

Influenza Resp Viruses

View full text Add to dashboard Cite

ObjectiveTo evaluate the safety of CSL's split‐virion inactivated trivalent 2009 Southern Hemisphere formulation influenza vaccine (TIV) in children.MethodsWe enrolled 1992 healthy children into three groups: Cohorts A, ≥6 months to <3 years; B, ≥3 years to <9 years; and C, ≥9 years to <18 years. Children received one or two doses of 0·25 ml (22·5 μg haemagglutinin) or 0·5 ml (45 μg) TIV, depending on age and prior vaccination history. We collected post‐vaccination solicited adverse event (AE) data (days 0–6), including fever (temperature: ≥37·5°C axilla, ≥38·0°C oral), unsolicited AEs (days 0–29) and serious AEs (SAEs) and new‐onset chronic illnesses (NOCIs; to day 180 after last vaccination).ResultsAt least one solicited AE was reported by 80%/78%/78% of children in Cohorts A, B and C, respectively. Systemic AEs were more common among Cohort A (72% of participants), and local AEs were more common among Cohort C (71% of participants). Fever was more common in younger cohorts, in influenza vaccine‐naïve children (29% of Cohort A receiving their first dose), and following first compared with second doses. Severe fever following a first dose prevented 20 participants receiving their second scheduled vaccine dose. A 7‐month‐old participant had a single uncomplicated febrile convulsion on the day of vaccination.ConclusionsNearly 80% of subjects reported at least one solicited AE following immunization. Fever prevalence was highest in vaccine‐naïve Cohort A participants, similar to other paediatric studies using CSL vaccine. Further research to understand fever‐related AEs in children following CSL's TIV is recommended.

show abstract

“…Results from this study have shown that vaccination of children aged from 5 through 18 years with LAIV was associated with a statistically significant reduction of medically attended acute respiratory illnesses in adults aged $35 years. 11 Similarly, in an earlier communitybased trial in 1968 in Tecumseh, Michigan, 86% of schoolchildren and 89% of school staff members were vaccinated against influenza. The adjusted community-based influenza attack rate among all age groups in Tecumseh during the 1968-1969 influenza season was one-third that of a neighboring comparison community, Adrian, Michigan.…”

Section: Results Of Vaccinating Schoolchildrenmentioning

confidence: 97%

A Theoretic Framework to Consider the Effect of Immunizing Schoolchildren Against Influenza: Implications for Research

Longini

2012

Pediatrics

View full text Add to dashboard Cite

The illness attack rate and annual morbidity caused by infection with influenza is high in schoolchildren. Because schoolchildren are 1 of the most important sources of community-wide transmission of influenza, vaccinating them could have a major effect on reducing morbidity and mortality in older adults. Stochastic modeling shows that a vaccination rate as low as 20% in schoolchildren reduces overall mortality in adults aged $64 years more effectively than a vaccination rate of 90% for older adults. Additional modeling shows that vaccinating schoolchildren against influenza is optimal for reducing morbidity and mortality caused by influenza in the overall population. Although supported by simulated models, the benefits of mass vaccination need to be confirmed in a realworld setting. The best way to demonstrate the effectiveness of mass vaccination of schoolchildren is to implement the process in several localities in several states by using properly designed studies that incorporate accurate viral surveillance with at least 10 pairs of intervention and comparison populations.

show abstract

Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children

Cited by 251 publications

References 30 publications

The role of vaccination in successful independent ageing

The role of vaccination in successful independent ageing

Safety and tolerability of a 2009 trivalent inactivated split‐virion influenza vaccine in infants, children and adolescents

A Theoretic Framework to Consider the Effect of Immunizing Schoolchildren Against Influenza: Implications for Research

Contact Info

Product

Resources

About